Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C65H85N17O12 |
| Molecular Weight | 1296.4796 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=C(C)NC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
InChI
InChIKey=HJNZCKLMRAOTMA-BRBGIFQRSA-N
InChI=1S/C65H85N17O12/c1-5-69-63(93)54-17-11-25-82(54)64(94)47(16-10-24-70-65(66)67)75-57(87)48(26-35(2)3)76-61(91)52(30-43-36(4)73-45-15-9-7-13-42(43)45)80-58(88)49(27-37-18-20-40(84)21-19-37)77-62(92)53(33-83)81-59(89)50(28-38-31-71-44-14-8-6-12-41(38)44)78-60(90)51(29-39-32-68-34-72-39)79-56(86)46-22-23-55(85)74-46/h6-9,12-15,18-21,31-32,34-35,46-54,71,73,83-84H,5,10-11,16-17,22-30,33H2,1-4H3,(H,68,72)(H,69,93)(H,74,85)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,86)(H,80,88)(H,81,89)(H4,66,67,70)/t46-,47-,48-,49-,50-,51-,52+,53-,54-/m0/s1
| Molecular Formula | C65H85N17O12 |
| Molecular Weight | 1296.4796 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10569560Curator's Comment: description was created based on several sources, including:
DOI: 10.1023/A:1008898216113 | https://www.ncbi.nlm.nih.gov/pubmed/16939388
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10569560
Curator's Comment: description was created based on several sources, including:
DOI: 10.1023/A:1008898216113 | https://www.ncbi.nlm.nih.gov/pubmed/16939388
Avorelin is a superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular weight polylactic glycolic acid to afford protracted and continuous release of the peptide from subcutaneous implants. Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued. Adverse events mainly related to androgen suppression (hot flushes, decreased libido and impotence) or the nature of the disease (skeletal pain).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1855 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10569560 DOI: 10.1023/A:1008898216113 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group. | 1999-12 |
|
| Manipulation of postnatal testosterone levels affects phallic and clitoral development in infant rhesus monkeys. | 1999-04 |
|
| Investigation of the role of postnatal testosterone in the expression of sex differences in behavior in infant rhesus macaques (Macaca mulatta). | 1999-04 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:21:34 GMT 2025
by
admin
on
Mon Mar 31 19:21:34 GMT 2025
|
| Record UNII |
FSB5837STQ
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID401339206
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
25074428
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
FSB5837STQ
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
SUB05618MIG
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
140703-49-7
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
100000086902
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103984
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
C99154
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY | |||
|
7080
Created by
admin on Mon Mar 31 19:21:34 GMT 2025 , Edited by admin on Mon Mar 31 19:21:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|